The Zantac-cancer connection is bolstered by recent voluntary recalls by the drug manfuacturers. The FDA found that many Zantac (ranitidine) samples contained "unacceptably" high levels of NDMA (N-Nitrosodimethylamine). NDMA causes cancer in animals and probably in humans as well.
In this article, our Zantac lawyers discuss:
- 1. Does Zantac cause cancer?
- 2. What kinds of cancer?
- 3. Why does Zantac have NDMA?
- 4. What is the evidence that NDMA causes cancer?
It is scientific fact that this chemical compound causes cancer in animals. Researchers use it on lab rats in order to give them cancer.2
The U.S. Department of Health and Human Services already said that NDMA is "reasonably anticipated" to cause humans to get cancer as well.3 And according to the EPA, NDMA is a "probable human carcinogen."4 Therefore, taking ranitidine with high NDMA levels arguably does cause cancer in people.
The FDA claims that ingesting .096 micrograms of NDMA per day is "reasonably safe." But when the FDA tested various lots of ranitidine, it found levels several times that in just one dose.5
Zantac users often took several doses a day over the course of years. It was marketed as an effective over-the-counter drug for heartburn. And doctors prescribed it for GERD and acid reflux.
Since just one ranitidine pill contains "unacceptable" levels of NDMA -- a "probable human carcinogen" -- plaintiffs' attorneys have a strong argument that regular Zantac use causes cancer in people.
There are possible links between taking NDMA (found in many ranitidine products) and the following cancers:
- Colorectal cancer,
- Gastric (stomach and intestinal) cancer,
- Liver cancer,
- Bladder cancer
- Esophageal cancer,
- Pancreatic cancer,
- Prostate cancer,
- Non-Hodgkins lymphoma, or
- Multiple myeloma
High levels of this chemical compound have also been found in other drugs, such as the blood-pressure medication Valsartan. And there is currently mass tort litigation against the Valsartan manufacturers for causing cancer in patients.
According to the FDA, NDMA is an "impurity." In other words, Zantac is contaminated. Either its original ingredients are tainted. Or it the NDMA creeps in during the manufacturing process. The FDA said:
This is something we are thoroughly aware of, and we have ongoing assessment, surveillance, compliance and pharmaceutical quality efforts across every product area to work to ensure similar impurities can be kept out of our drug supply.6
But according to Valisure (an online pharmacy), NDMA is not an impurity. Instead, it is a byproduct. Valisure claims that Zantac causes NDMA to manifest in the body during the digestion process when the active ingredient breaks down.
The FDA responded that Valisure's methods of simulating human digestion were unrealistic. This is because Valisure exposed the ranitidine to unnaturally high heat (130 degrees Fahrenheit). And Valisure added more nitrates than a typical person would ingest.7 The FDA said:
FDA ... developed a simulated gastric fluid (SGF) model to ... estimate the biological significance of in vitro findings. The SGF and simulated intestinal fluid (SIF) models are intended to detect the formation of NDMA in systems that approximate the stomach and intestinal fluids, respectively. The results of these tests showed no additional NDMA generated in the stomach.8
However, Valisure claims it also detected NDMA in only 37 degrees heat and with typical amounts of nitrates (like those in process meats). The FDA has yet to reveal how much NDMA it found using Valisure's methods.9
Either way, Zantac users are likely ingesting far more NDMA that what the FDA says is safe.
There is ample evidence NDMA causes cancer in animals:
- A 1989 toxicological profile by the Agency for Toxic Substances and Disease Registry (ATSDR) spelled out how NDMA caused mice to develop liver, stomach, and lung cancer.10
- A 1991 medical journal article chronicled how dosing rats with the compound caused liver and esophageal tumors.11
- The World Health Organization said studies "positively associate" NDMA with gastric or colorectal cancer.12
As discussed earlier, the EPA calls NDMA a "probable human carcinogen.".13 And a 2018 study of Valsartan (that has the compound) showed "increases in risk were observed for colorectal cancer ... and for uterine cancer."14
NDMA has also long been used as a poison:
- In 1978, a man tried to murder his wife by putting NDMA in her jam. She ended up dying from liver failure.15
- In 1978, a Nebraska man put NDMA in a drink. It caused two other people to die.16
- In 2013, a student put NDMA in the dormitory water cooler. This lead to his roommate's death.17
Are you a Zantac victim? Contact us for help...
Did you get cancer after taking Zantac? You may have grounds to join the Zantac MDL lawsuit against the drug manufacturers.
There is a statute of limitations to sue. So phone our Zantac lawyers at (877) 504-7750 now. Or fill out the form on this page. We offer free consultations.
Our goal? To get you the biggest settlement possible in your case. And we take no payment unless we win.
- Toxicological Profile Forn-nitrosodimethylamine, Agency For Toxic Substances And Disease Registry (ATSDR) U.S. Public Health Service in Collaboration With U.S. Environmental Protection Agency (EPA) (December 1989).
- Technical Fact Sheet – N-Nitroso-dimethylamine (NDMA), EPA (January 2014).
- Laboratory Tests, ranitidine, FDA (November 1, 2019).
- Statement on new testing results, including low levels of impurities in ranitidine drugs, FDA (November 1, 2019).
- Tanya Lewis, "What We Know about the Possible Carcinogen Found in Zantac", Scientific American (October 28, 2019).
- See note 6.
- See note 7.
- See note 3.
- See note 2.
- N-Nitroso-dimethylamine (NDMA), World Health Organization (WHO).
- See note 4.
- Anton Pottegård, Kasper Bruun Kristensen, Martin Thomsen Ernst, Nanna Borup Johansen, Pierre Quartarolo, Jesper Hallas, "Use of N-nitrosodimethylamine (NDMA) contaminated Valsartan products and risk of cancer: Danish nationwide cohort study", BMJ (September 2018).
- Karsten Strey: "Die Welt der Gifte", Lehmanns, 2. Edition p. 193.
- Roueche, Betron, "Annals of Medicine – The Prognosis for this Patient is Horrible", The New Yorker: 57–71 (January 25, 1982).
- "15 days log in hospital". Archived from the original on 2014-01-09. Retrieved 2013-04-30.